{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Uveal+Melanoma+AJCC+v7", "query": { "condition": "Stage IV Uveal Melanoma AJCC v7" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Uveal+Melanoma+AJCC+v7&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:04:59.188Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01143402", "title": "Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Iris Melanoma", "Medium/Large Size Posterior Uveal Melanoma", "Ocular Melanoma With Extraocular Extension", "Recurrent Uveal Melanoma", "Small Size Posterior Uveal Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2010-06", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 32, "location_summary": "Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01143402" }, { "nct_id": "NCT02359851", "title": "Pembrolizumab in Treating Patients With Advanced Uveal Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIA Uveal Melanoma", "Stage IIIB Uveal Melanoma", "Stage IIIC Uveal Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-05", "completion_date": "2019-08-27", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 2, "location_summary": "Chicago, Illinois • Nashville, Tennessee", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02359851" }, { "nct_id": "NCT01989572", "title": "Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Iris Melanoma", "Medium/Large Size Posterior Uveal Melanoma", "Mucosal Melanoma", "Ocular Melanoma With Extraocular Extension", "Recurrent Melanoma", "Recurrent Uveal Melanoma", "Small Size Posterior Uveal Melanoma", "Stage IIA Cutaneous Melanoma AJCC v6 and v7", "Stage IIA Uveal Melanoma AJCC v7", "Stage IIB Cutaneous Melanoma AJCC v6 and v7", "Stage IIB Uveal Melanoma AJCC v7", "Stage IIC Cutaneous Melanoma AJCC v6 and v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIA Uveal Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Uveal Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IIIC Uveal Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Tyrosinase Peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 815, "start_date": "2000-02-23", "completion_date": "2013-01-31", "has_results": true, "last_update_posted_date": "2020-07-07", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 148, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01989572" }, { "nct_id": "NCT01473004", "title": "SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Sir-Spheres®", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2011-10-31", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473004" }, { "nct_id": "NCT02363283", "title": "Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Glembatumumab Vedotin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2015-09-16", "completion_date": "2018-07-02", "has_results": true, "last_update_posted_date": "2020-08-21", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02363283" }, { "nct_id": "NCT01961115", "title": "Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucosal Melanoma", "Recurrent Melanoma", "Recurrent Uveal Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIA Uveal Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIB Uveal Melanoma", "Stage IIIC Skin Melanoma", "Stage IIIC Uveal Melanoma", "Stage IV Skin Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "MELITAC 12.1 Peptide Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-09-13", "completion_date": "2017-05-18", "has_results": true, "last_update_posted_date": "2018-06-08", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Durham, North Carolina • Cleveland, Ohio + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01961115" }, { "nct_id": "NCT02129075", "title": "A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Melanoma", "Melanoma of Unknown Primary", "Mucosal Melanoma", "Ocular Melanoma", "Stage IIB Cutaneous Melanoma AJCC v6 and v7", "Stage IIC Cutaneous Melanoma AJCC v6 and v7", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Recombinant Flt3 Ligand", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2014-04-09", "completion_date": "2018-05-18", "has_results": true, "last_update_posted_date": "2021-11-16", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 7, "location_summary": "Chicago, Illinois • New York, New York • Durham, North Carolina + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02129075" }, { "nct_id": "NCT02158520", "title": "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Mucosal Melanoma", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-10-18", "completion_date": "2019-10-30", "has_results": true, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 13, "location_summary": "San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02158520" }, { "nct_id": "NCT01979523", "title": "Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Uprosertib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2013-11-21", "completion_date": "2026-07-02", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 5, "location_summary": "Atlanta, Georgia • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01979523" }, { "nct_id": "NCT01585194", "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2012-11-29", "completion_date": "2024-05-14", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-05-22T04:04:59.188Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585194" } ] }